IL289198A - Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation - Google Patents

Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation

Info

Publication number
IL289198A
IL289198A IL289198A IL28919821A IL289198A IL 289198 A IL289198 A IL 289198A IL 289198 A IL289198 A IL 289198A IL 28919821 A IL28919821 A IL 28919821A IL 289198 A IL289198 A IL 289198A
Authority
IL
Israel
Prior art keywords
oxobutan
diazaspiro
octane
carboxylate
oxo
Prior art date
Application number
IL289198A
Other languages
English (en)
Hebrew (he)
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of IL289198A publication Critical patent/IL289198A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL289198A 2019-06-24 2021-12-21 Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation IL289198A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Publications (1)

Publication Number Publication Date
IL289198A true IL289198A (en) 2022-02-01

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289198A IL289198A (en) 2019-06-24 2021-12-21 Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation

Country Status (11)

Country Link
US (1) US20220267341A1 (enExample)
EP (1) EP3986399A4 (enExample)
JP (2) JP7617043B2 (enExample)
CN (1) CN114364380A (enExample)
AU (1) AU2020304001B2 (enExample)
BR (1) BR112021026380A2 (enExample)
CA (1) CA3144600A1 (enExample)
IL (1) IL289198A (enExample)
MA (1) MA56550A (enExample)
MX (2) MX2022000069A (enExample)
WO (1) WO2020263847A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US9758525B2 (en) * 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20151416A1 (es) * 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Also Published As

Publication number Publication date
WO2020263847A1 (en) 2020-12-30
AU2020304001B2 (en) 2026-04-09
JP2025069143A (ja) 2025-04-30
MX2022000069A (es) 2022-05-24
MA56550A (fr) 2022-04-27
US20220267341A1 (en) 2022-08-25
KR20220061088A (ko) 2022-05-12
CA3144600A1 (en) 2020-12-30
EP3986399A4 (en) 2023-06-07
JP7617043B2 (ja) 2025-01-17
JP2022539342A (ja) 2022-09-08
AU2020304001A1 (en) 2022-01-27
CN114364380A (zh) 2022-04-15
MX2025002579A (es) 2025-04-02
BR112021026380A2 (pt) 2022-05-10
EP3986399A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EP3934652A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
IL304534B1 (en) Methods for the preparation of 4-[(13as)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl- hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro benzothiophene-3-carbonitrile
GB201910389D0 (en) Novel compounds, methods for their manufacture, and uses thereof
AU2018271990A1 (en) Covalent inhibitors of KRAS
PL4055126T3 (pl) Kompozycje i sposoby oraz zastosowania z nimi związane
GB2577981B (en) Methods, products & Uses relating thereto
ES3063994T3 (en) Cd73 inhibitor, preparation method therefor and application thereof
WO2017011340A3 (en) Proteins and immunizing compositions containing klebsiella proteins and methods of use
EP3943625A4 (en) ECO-FRIENDLY NON-CYANIDIC GOLD EXTRACTOR, PROCESS FOR ITS PRODUCTION AND ITS USE
EP4082534A4 (en) SOLID PREPARATION, ITS PREPARATION METHOD AND ITS USE
IL290331A (en) RNA-directing ligands, preparations containing them, and methods for their preparation and use
EP4085916A4 (en) PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR GRAFT VERSUS HOST DISEASE
GB201813648D0 (en) Methods, products & uses relating thereto
EP4082514A4 (en) PASTE COMPOSITION FOR DENTAL USE AND METHOD FOR THE PRODUCTION THEREOF
IL289198A (en) Solid forms of tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-5,2-diazaspiro[4.3]octane- 5-carboxylate and methods for their preparation
GB201912021D0 (en) Methods, products & Uses relating thereto
PL4001260T3 (pl) Pochodna dibromobenzylu, jej stereoizomer lub sól, oraz sposób jej wytwarzania i jej zastosowanie
WO2015185993A9 (en) Methods for improving fillet quality in farmed fish
EP4025384A4 (en) MAGNETORHEOLOGICAL FINISHING HEAD WITH HIGH REMOTION RATE
EP3988593A4 (en) BLOCK COPOLYMER INTERMEDIATE, BLOCK COPOLYMER AND METHODS OF PRODUCING THEM
GB201910299D0 (en) Medical uses, methods and uses
GB201907832D0 (en) Medical uses, methods and uses
GB201912016D0 (en) Methods, products & uses relating thereto
WO2015143240A3 (en) Compositions and methods comprising 2-(acylamino)imidazoles
WO2018075598A8 (en) SYNTHESIS OF EZH2 INHIBITORS